Global Point Of Care Diagnostics Market Overview

Global Point of Care Diagnostics Market was valued at USD 32.91 billion in 2022 and is expected to reach USD 63.67 billion by the year 2030, at a CAGR of 8.6%.

Point-of-care testing (POCT) is critical for detecting analytes close to the patient, allowing for better disease diagnosis, monitoring, and management. It allows for quick medical decisions because diseases can be diagnosed at an early stage, resulting in better health outcomes for patients by allowing for the early start of treatment. POC testing was first used in 1962 with the development of a method for rapid analysis of blood glucose, and soon after, in 1977, rapid pregnancy tests were developed, ushering in a trend for personalized diagnostics. POC diagnostic devices for monitoring glucose, ECG, blood pressure, and other parameters have greatly aided clinical and personalized healthcare.

Several prospective POCDs have been developed in recent years, providing a platform for next-generation POCT. The biosensor is the most important component of POCD and is directly responsible for an assay's bioanalytical performance. Several label-free biosensors, including electrochemical, surface plasmon resonance (SPR), white light reflectance spectroscopy (WLRS), and others, have been developed and are being used to improve POCD. The growing importance of point-of-care diagnostics in environmental monitoring and public health necessitates the incorporation of technologies that enable simple networking, making it easier for healthcare professionals to interpret test results accurately. Thus, in the coming years, remote access integration of POC tests and their networking is expected to open up new avenues for the industry.

Market Dynamics And Factors For Point of Care Diagnostics Market

Drivers:

Increasing Prevalence Of Chronic Diseases

The POCD market is poised for significant growth as the prevalence of chronic diseases such as diabetes, and kidney disease, and as the prevalence of cardiovascular disease rises, necessitating long-term care and frequent monitoring, so will the demand for cost-effective and innovative point-of-care diagnostic products. Chronic diseases are becoming more common all over the world. Changes in societal behaviour, as well as an aging population, are all contributing to a steady rise in these common and costly long-term health issues. As the middle class grows and urbanization accelerates, people are becoming more sedentary. As a result, obesity rates and cases of diseases such as diabetes are increasing. Chronic disease prevalence is expected to rise by 57% by 2020, according to the World Health Organization. As population growth is expected to be greatest in developing countries, emerging markets will be the hardest hit. As a result, the point care diagnostic market is expected to grow during the forecast period.

Restraints:

Adoption Of Point-Of-Care Diagnostics Is Inadequate

The majority of point-of-care diagnostics tests are performed by clinical professionals with less laboratory experience, such as nurses. Because hospitals have a large number of patients, these individuals concentrate on patient care and are constantly under pressure to provide prompt treatment. The sample collection and all other processes that clinical personnel perform while performing point-of-care diagnostics tests are generally unfamiliar. Furthermore, it has been observed that in most cases, the opinion of lab experts or healthcare workers is ignored. As a result, the decrease in the adoption of point-of-care diagnostics is impeding market growth.

Opportunity:

Technological Advancement In POC Diagnostic

Technological advancements have resulted in the development of several novel point-of-care diagnostic devices for a variety of applications. Recent advances in biosensing technology, microfluidics, and paper-based diagnostics will improve diagnostic quality and efficiency. Scientists and entrepreneurs have had a significant impact on the development of next-generation POC diagnostic devices based on cutting-edge technologies such as Artificial Intelligence (AI), the Internet of Things (IoT), and so on. POC technologies combined with smart information and communications technology (ICT) hold great promise for managing resources sustainably and improving healthcare delivery in rural areas. Thus, the future holds a lucrative opportunity for the point care diagnostic market.

Market Dynamics And Factors For Point Care Diagnostics Market

By Application, the glucose monitoring segment is forecasted to dominate the point care diagnostic market in the upcoming future. Glucose monitoring is the most common application for point-of-care diagnostic tests. Diabetes patients are monitored using point-of-care testing (POCT) for glucose at the bedside, at home, or in the hospital. The use of point-of-care (POC) glucose meters in self-monitoring of blood glucose is a valuable tool for managing glycemic control in diabetic patients. In adaptive clinical trials involving dose adjustment and blinded studies, glucose testing at the point of care has been used frequently. The most common tests are glucose and HBA1C. Small blood volumes of whole or venous samples are used in CLIA-Waived and moderately complex platforms. Results will be available in minutes. To eliminate potential preanalytical, analytical, and post-analytical errors, the POCT program for glucose should be evaluated. Thus, consolidating the growth of this segment in the projected timeframe. 

By platform, the immunoassays segment is expected to have the highest share of the point of care diagnostic market in the projected timeframe. Immunoassays are valuable tools and the traditional gold standard in infectious disease diagnostics, detecting microbial antigens of pathogen-specific antibodies in crude samples such as blood, saliva, or nasal swabs, saving significant time when compared to culturing approaches, which is a critical bottleneck for in treating patients with severe disease. Enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), and chemiluminescent immunoassays are the most commonly used immunoassays for infectious disease serological testing (CLIAs). LIFAs are an especially appealing option because they require less operator skill and have the potential to be used in point-of-care settings. Thus, driving the growth of the immunoassays segment. 

By end-users, the diagnostic laboratories segment is expected to dominate the point care diagnostic market in the forecasted timeframe. The prevalence of various ailments is increasing the point care diagnostic market in diagnostic laboratories. Because of the increasing number of COVID-19 cases worldwide and the governments of various countries' repeated requests for people to be tested, many stand-alone diagnostic centers, hospital-based diagnostic labs, and diagnostic chains have been approved and accredited to perform COVID-19 tests. Thus, strengthening the development of this segment.

Regional Analysis Of Point of Care Diagnostics Market

The North American region is anticipated to have the highest share of the point of care diagnostic market in the forecast period due to the growing awareness about the diagnosis of diseases. The global POCT market is expected to grow at a compound annual growth rate (CAGR) of 9.8 percent from 2016 to 2021, from US$ 23.16 billion in 2016. North America accounts for the majority of the global POCT market due to high healthcare affordability, premium healthcare infrastructure, and a high level of patient awareness.

The Asia Pacific region is expected to have the second-highest share of the point of care diagnostic market in the projected timeframe. In India, where healthcare resources and infrastructure are distributed unevenly, point-of-care tests are becoming an important tool for increasing diagnostic coverage of the population. India is a developing economy and a popular location for market investments. The development of healthcare infrastructure, combined with an increase in the prevalence of chronic and targeted diseases such as diabetes and cancer, as well as infectious diseases such as HIV, syphilis, COVID-19, RSV, and others, is expected to drive the regional market. Aside from the growing geriatric population, rising stress levels, and increased use of novel immunoassay techniques, strengthening the development of the point-of-care diagnostic market during the forecast period.

The point-of-care diagnostic market in the European region is expected to develop at a significant growth in the projected timeframe. COVID-19 has had a significant impact on Europe, particularly France. As a result of the region's exponential increase in COVID-19 cases, the European economy is suffering. With a high number of fatalities, Spain, Italy, Germany, France, and the United Kingdom are among the most affected European countries. According to the International Health Regulation, the current coronavirus (COVID-19) outbreak has been declared a Public Health Emergency of International Concern by WHO. The rising number of coronavirus infections and demand for advanced diagnostic solutions present a favorable opportunity for the region's adoption of point-of-care diagnostic kits. Rising investments and business activities by industry players are also expected to drive the point-of-care diagnostic market during the forecast period.

Covid-19 Impact Analysis On Point of Care Diagnostics Market

The COVID-19 pandemic has shifted the POC testing landscape in the world. It has fuelled research into the development of testing strategies that are both quick and inexpensive and can be used as point-of-care testing in the community. The pandemic has hastened the trend of experimenting with decentralization. Reaching out to patients outside of laboratories, hospitals, and homes enables a faster response to clinical needs. Point-of-care (POC) detection technologies that enable decentralized, rapid, sensitive, low-cost COVID-19 infection diagnostics are desperately needed around the world. The field of COVID-19 POC diagnostics is rapidly evolving, with many technologies approved for commercialization in the last ten months. In this Perspective, the current state of POC technologies for COVID-19 infection diagnosis and monitoring, as well as future challenges in COVID-19 diagnostics. As the COVID-19 pandemic becomes endemic, the advances made this year will most likely be used to predict future outbreaks and pandemics.

Top Key Players Covered In Point Care Diagnostics Market

• F. Hoffmann-La Roche Ltd (Basel, Switzerland)
• Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
• Abbott Laboratories (Illinois, U.S.)
• Quest Diagnostics Incorporated (New Jersey, U.S.)
• BD (Franklin Lakes, U.S.)
• BioMerieux SA (Marcy l'Etoile, France)
• Cardinal Health, Inc. (Ohio, U.S.)
• Mesa Biotech (California, U.S.)
• Cepheid (California, U.S.)
• Trinity Biotech (Bray, Ireland)
• Quidel Corporation (San Diego, U.S.)
• Bio-Rad Laboratories Inc. (California, U.S.) and Other Major Players.

Key Industry Development In The Point Of Care Diagnostics Market

In January 2022, Roche launched its Cobas Pulse System in countries that accept the CE Mark. This is the latest generation of connected point-of-care solutions from Roche Diagnostics for professional blood glucose management.

In February 2021, Mesa Biotech, Inc. a privately held point-of-care molecular diagnostic company, has been acquired by Thermo Fisher Scientific Inc. Mesa Biotech created the Accula System, a point-of-care PCR-based infectious disease testing platform.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Application
 3.2 By Platform
 3.3 By End-User

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Point of Care Diagnostics Market by Application
 5.1 Point of Care Diagnostics Market Overview Snapshot and Growth Engine
 5.2 Point of Care Diagnostics Market Overview
 5.3 Infectious Disease Testing Products
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Infectious Disease Testing Products: Grographic Segmentation
 5.4 Glucose Monitoring Products
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Glucose Monitoring Products: Grographic Segmentation
 5.5 Pregnancy & Fertility Testing Products
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Pregnancy & Fertility Testing Products: Grographic Segmentation
 5.6 Cardiometabolic Monitoring Products
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Cardiometabolic Monitoring Products: Grographic Segmentation
 5.7 Others
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Others: Grographic Segmentation

Chapter 6: Point of Care Diagnostics Market by Platform
 6.1 Point of Care Diagnostics Market Overview Snapshot and Growth Engine
 6.2 Point of Care Diagnostics Market Overview
 6.3 Molecular Diagnostic
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Molecular Diagnostic: Grographic Segmentation
 6.4 Immunoassays
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Immunoassays: Grographic Segmentation
 6.5 Lateral Flow Assays
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Lateral Flow Assays: Grographic Segmentation
 6.6 Others
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Others: Grographic Segmentation

Chapter 7: Point of Care Diagnostics Market by End-User
 7.1 Point of Care Diagnostics Market Overview Snapshot and Growth Engine
 7.2 Point of Care Diagnostics Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Grographic Segmentation
 7.4 Clinics
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Clinics: Grographic Segmentation
 7.5 Diagnostic Laboratories
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Diagnostic Laboratories: Grographic Segmentation
 7.6 Home Care
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size (2016-2028F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Home Care: Grographic Segmentation
 7.7 Others
  7.7.1 Introduction and Market Overview
  7.7.2 Historic and Forecasted Market Size (2016-2028F)
  7.7.3 Key Market Trends, Growth Factors and Opportunities
  7.7.4 Others: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Point of Care Diagnostics Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Point of Care Diagnostics Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Point of Care Diagnostics Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 F. HOFFMANN-LA ROCHE LTD
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 THERMO FISHER SCIENTIFIC INC.
 8.4 ABBOTT LABORATORIES
 8.5 QUEST DIAGNOSTICS INCORPORATED
 8.6 BD
 8.7 FRANKLIN LAKES
 8.8 BIOMERIEUX SA
 8.9 MARCY L'ETOILE
 8.10 FRANCE
 8.11 CARDINAL HEALTH INC.
 8.12 OHIO
 8.13 MESA BIOTECH.
 8.14 CEPHEID
 8.15 TRINITY BIOTECH
 8.16 QUIDEL CORPORATION
 8.17 BIO-RAD LABORATORIES INC.
 8.18 OTHER MAJOR PLAYERS

Chapter 9: Global Point of Care Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Application
  9.2.1 Infectious Disease Testing Products
  9.2.2 Glucose Monitoring Products
  9.2.3 Pregnancy & Fertility Testing Products
  9.2.4 Cardiometabolic Monitoring Products
  9.2.5 Others
 9.3 Historic and Forecasted Market Size By Platform
  9.3.1 Molecular Diagnostic
  9.3.2 Immunoassays
  9.3.3 Lateral Flow Assays
  9.3.4 Others
 9.4 Historic and Forecasted Market Size By End-User
  9.4.1 Hospitals
  9.4.2 Clinics
  9.4.3 Diagnostic Laboratories
  9.4.4 Home Care
  9.4.5 Others

Chapter 10: North America Point of Care Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Application
  10.4.1 Infectious Disease Testing Products
  10.4.2 Glucose Monitoring Products
  10.4.3 Pregnancy & Fertility Testing Products
  10.4.4 Cardiometabolic Monitoring Products
  10.4.5 Others
 10.5 Historic and Forecasted Market Size By Platform
  10.5.1 Molecular Diagnostic
  10.5.2 Immunoassays
  10.5.3 Lateral Flow Assays
  10.5.4 Others
 10.6 Historic and Forecasted Market Size By End-User
  10.6.1 Hospitals
  10.6.2 Clinics
  10.6.3 Diagnostic Laboratories
  10.6.4 Home Care
  10.6.5 Others
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Point of Care Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Application
  11.4.1 Infectious Disease Testing Products
  11.4.2 Glucose Monitoring Products
  11.4.3 Pregnancy & Fertility Testing Products
  11.4.4 Cardiometabolic Monitoring Products
  11.4.5 Others
 11.5 Historic and Forecasted Market Size By Platform
  11.5.1 Molecular Diagnostic
  11.5.2 Immunoassays
  11.5.3 Lateral Flow Assays
  11.5.4 Others
 11.6 Historic and Forecasted Market Size By End-User
  11.6.1 Hospitals
  11.6.2 Clinics
  11.6.3 Diagnostic Laboratories
  11.6.4 Home Care
  11.6.5 Others
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Point of Care Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Application
  12.4.1 Infectious Disease Testing Products
  12.4.2 Glucose Monitoring Products
  12.4.3 Pregnancy & Fertility Testing Products
  12.4.4 Cardiometabolic Monitoring Products
  12.4.5 Others
 12.5 Historic and Forecasted Market Size By Platform
  12.5.1 Molecular Diagnostic
  12.5.2 Immunoassays
  12.5.3 Lateral Flow Assays
  12.5.4 Others
 12.6 Historic and Forecasted Market Size By End-User
  12.6.1 Hospitals
  12.6.2 Clinics
  12.6.3 Diagnostic Laboratories
  12.6.4 Home Care
  12.6.5 Others
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Point of Care Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Application
  13.4.1 Infectious Disease Testing Products
  13.4.2 Glucose Monitoring Products
  13.4.3 Pregnancy & Fertility Testing Products
  13.4.4 Cardiometabolic Monitoring Products
  13.4.5 Others
 13.5 Historic and Forecasted Market Size By Platform
  13.5.1 Molecular Diagnostic
  13.5.2 Immunoassays
  13.5.3 Lateral Flow Assays
  13.5.4 Others
 13.6 Historic and Forecasted Market Size By End-User
  13.6.1 Hospitals
  13.6.2 Clinics
  13.6.3 Diagnostic Laboratories
  13.6.4 Home Care
  13.6.5 Others
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Point of Care Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Application
  14.4.1 Infectious Disease Testing Products
  14.4.2 Glucose Monitoring Products
  14.4.3 Pregnancy & Fertility Testing Products
  14.4.4 Cardiometabolic Monitoring Products
  14.4.5 Others
 14.5 Historic and Forecasted Market Size By Platform
  14.5.1 Molecular Diagnostic
  14.5.2 Immunoassays
  14.5.3 Lateral Flow Assays
  14.5.4 Others
 14.6 Historic and Forecasted Market Size By End-User
  14.6.1 Hospitals
  14.6.2 Clinics
  14.6.3 Diagnostic Laboratories
  14.6.4 Home Care
  14.6.5 Others
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. POINT OF CARE DIAGNOSTICS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. POINT OF CARE DIAGNOSTICS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. POINT OF CARE DIAGNOSTICS MARKET COMPETITIVE RIVALRY
TABLE 005. POINT OF CARE DIAGNOSTICS MARKET THREAT OF NEW ENTRANTS
TABLE 006. POINT OF CARE DIAGNOSTICS MARKET THREAT OF SUBSTITUTES
TABLE 007. POINT OF CARE DIAGNOSTICS MARKET BY APPLICATION
TABLE 008. INFECTIOUS DISEASE TESTING PRODUCTS MARKET OVERVIEW (2016-2028)
TABLE 009. GLUCOSE MONITORING PRODUCTS MARKET OVERVIEW (2016-2028)
TABLE 010. PREGNANCY & FERTILITY TESTING PRODUCTS MARKET OVERVIEW (2016-2028)
TABLE 011. CARDIOMETABOLIC MONITORING PRODUCTS MARKET OVERVIEW (2016-2028)
TABLE 012. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 013. POINT OF CARE DIAGNOSTICS MARKET BY PLATFORM
TABLE 014. MOLECULAR DIAGNOSTIC MARKET OVERVIEW (2016-2028)
TABLE 015. IMMUNOASSAYS MARKET OVERVIEW (2016-2028)
TABLE 016. LATERAL FLOW ASSAYS MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. POINT OF CARE DIAGNOSTICS MARKET BY END-USER
TABLE 019. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 020. CLINICS MARKET OVERVIEW (2016-2028)
TABLE 021. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 022. HOME CARE MARKET OVERVIEW (2016-2028)
TABLE 023. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 024. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION (2016-2028)
TABLE 025. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (2016-2028)
TABLE 026. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY END-USER (2016-2028)
TABLE 027. N POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 028. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION (2016-2028)
TABLE 029. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (2016-2028)
TABLE 030. EUROPE POINT OF CARE DIAGNOSTICS MARKET, BY END-USER (2016-2028)
TABLE 031. POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 032. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION (2016-2028)
TABLE 033. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (2016-2028)
TABLE 034. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET, BY END-USER (2016-2028)
TABLE 035. POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (2016-2028)
TABLE 038. MIDDLE EAST & AFRICA POINT OF CARE DIAGNOSTICS MARKET, BY END-USER (2016-2028)
TABLE 039. POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 040. SOUTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION (2016-2028)
TABLE 041. SOUTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (2016-2028)
TABLE 042. SOUTH AMERICA POINT OF CARE DIAGNOSTICS MARKET, BY END-USER (2016-2028)
TABLE 043. POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 044. F. HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 045. F. HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 046. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 047. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 048. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 049. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 050. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. ABBOTT LABORATORIES: SNAPSHOT
TABLE 051. ABBOTT LABORATORIES: BUSINESS PERFORMANCE
TABLE 052. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 053. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. QUEST DIAGNOSTICS INCORPORATED: SNAPSHOT
TABLE 054. QUEST DIAGNOSTICS INCORPORATED: BUSINESS PERFORMANCE
TABLE 055. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
TABLE 056. QUEST DIAGNOSTICS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. BD: SNAPSHOT
TABLE 057. BD: BUSINESS PERFORMANCE
TABLE 058. BD: PRODUCT PORTFOLIO
TABLE 059. BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. FRANKLIN LAKES: SNAPSHOT
TABLE 060. FRANKLIN LAKES: BUSINESS PERFORMANCE
TABLE 061. FRANKLIN LAKES: PRODUCT PORTFOLIO
TABLE 062. FRANKLIN LAKES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. BIOMERIEUX SA: SNAPSHOT
TABLE 063. BIOMERIEUX SA: BUSINESS PERFORMANCE
TABLE 064. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 065. BIOMERIEUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. MARCY L'ETOILE: SNAPSHOT
TABLE 066. MARCY L'ETOILE: BUSINESS PERFORMANCE
TABLE 067. MARCY L'ETOILE: PRODUCT PORTFOLIO
TABLE 068. MARCY L'ETOILE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. FRANCE: SNAPSHOT
TABLE 069. FRANCE: BUSINESS PERFORMANCE
TABLE 070. FRANCE: PRODUCT PORTFOLIO
TABLE 071. FRANCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. CARDINAL HEALTH INC.: SNAPSHOT
TABLE 072. CARDINAL HEALTH INC.: BUSINESS PERFORMANCE
TABLE 073. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
TABLE 074. CARDINAL HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. OHIO: SNAPSHOT
TABLE 075. OHIO: BUSINESS PERFORMANCE
TABLE 076. OHIO: PRODUCT PORTFOLIO
TABLE 077. OHIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. MESA BIOTECH.: SNAPSHOT
TABLE 078. MESA BIOTECH.: BUSINESS PERFORMANCE
TABLE 079. MESA BIOTECH.: PRODUCT PORTFOLIO
TABLE 080. MESA BIOTECH.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. CEPHEID: SNAPSHOT
TABLE 081. CEPHEID: BUSINESS PERFORMANCE
TABLE 082. CEPHEID: PRODUCT PORTFOLIO
TABLE 083. CEPHEID: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. TRINITY BIOTECH: SNAPSHOT
TABLE 084. TRINITY BIOTECH: BUSINESS PERFORMANCE
TABLE 085. TRINITY BIOTECH: PRODUCT PORTFOLIO
TABLE 086. TRINITY BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. QUIDEL CORPORATION: SNAPSHOT
TABLE 087. QUIDEL CORPORATION: BUSINESS PERFORMANCE
TABLE 088. QUIDEL CORPORATION: PRODUCT PORTFOLIO
TABLE 089. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 089. BIO-RAD LABORATORIES INC.: SNAPSHOT
TABLE 090. BIO-RAD LABORATORIES INC.: BUSINESS PERFORMANCE
TABLE 091. BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 092. BIO-RAD LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 092. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 093. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 094. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 095. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY APPLICATION
FIGURE 012. INFECTIOUS DISEASE TESTING PRODUCTS MARKET OVERVIEW (2016-2028)
FIGURE 013. GLUCOSE MONITORING PRODUCTS MARKET OVERVIEW (2016-2028)
FIGURE 014. PREGNANCY & FERTILITY TESTING PRODUCTS MARKET OVERVIEW (2016-2028)
FIGURE 015. CARDIOMETABOLIC MONITORING PRODUCTS MARKET OVERVIEW (2016-2028)
FIGURE 016. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 017. POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY PLATFORM
FIGURE 018. MOLECULAR DIAGNOSTIC MARKET OVERVIEW (2016-2028)
FIGURE 019. IMMUNOASSAYS MARKET OVERVIEW (2016-2028)
FIGURE 020. LATERAL FLOW ASSAYS MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY END-USER
FIGURE 023. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 024. CLINICS MARKET OVERVIEW (2016-2028)
FIGURE 025. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 026. HOME CARE MARKET OVERVIEW (2016-2028)
FIGURE 027. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 028. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. EUROPE POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. MIDDLE EAST & AFRICA POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. SOUTH AMERICA POINT OF CARE DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)